Skip to content

Shattuck Labs, Inc. STTK Return on equity

Return on equity at other companies

Eli Lilly logo
Eli LillyLLY
107.6%+29.9pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
26.4%-3.0pp
Amgen logo
AmgenAMGN
101.3%-4.4pp
AbbVie logo
AbbVieABBV
89%+32.7pp
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-48.4%-15.4pp
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-88.8%

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Calculated from Shattuck Labs, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s return on equity?
Shattuck Labs, Inc. (STTK) reported return on equity of -61% in Q1 2026.
How has Shattuck Labs, Inc.'s return on equity changed year-over-year?
Shattuck Labs, Inc.'s return on equity increased by 15.1% year-over-year, from -71.9% to -61%.
What is the long-term trend for Shattuck Labs, Inc.'s return on equity?
Over 3 years (2022 to 2025), Shattuck Labs, Inc.'s return on equity has grown at a 9.8% compound annual growth rate (CAGR), from -45.5% to -60.3%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.